Tibet Aim Pharm Inc (002826) - Total Liabilities

Latest as of March 2026: CN¥265.27 Million CNY ≈ $38.82 Million USD

Based on the latest financial reports, Tibet Aim Pharm Inc (002826) has total liabilities worth CN¥265.27 Million CNY (≈ $38.82 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Tibet Aim Pharm Inc (002826) equity growth momentum to track the company's year-over-year net asset growth rate.

Tibet Aim Pharm Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Tibet Aim Pharm Inc's total liabilities have evolved over time, based on quarterly financial data. See 002826 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Tibet Aim Pharm Inc Competitors by Total Liabilities

The table below lists competitors of Tibet Aim Pharm Inc ranked by their total liabilities.

Company Country Total Liabilities
Taiyuan Lionhead Cement Co Ltd
SHG:600539
China CN¥104.58 Million
Kneat.com Inc
TO:KSI
Canada CA$56.74 Million
Unipar Carbocloro S.A
SA:UNIP3
Brazil R$5.57 Billion
Viromed Medical AG
DU:Q11
Germany €69.84 Million
Frontera Energy Corp
TO:FEC
Canada CA$1.20 Billion
Albaraka Turk Katilim Bankasi AS
IS:ALBRK
Turkey TL397.50 Billion
Levinstein Eng
TA:LEVI
Israel ILA2.21 Billion
Nanjing CEC Environmental Protect
SHE:300172
China CN¥914.55 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Tibet Aim Pharm Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tibet Aim Pharm Inc (002826) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.78 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tibet Aim Pharm Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tibet Aim Pharm Inc (2013–2025)

The table below shows the annual total liabilities of Tibet Aim Pharm Inc from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥201.65 Million
≈ $29.51 Million
+11.48%
2024-12-31 CN¥180.89 Million
≈ $26.47 Million
+1.81%
2023-12-31 CN¥177.68 Million
≈ $26.00 Million
-33.75%
2022-12-31 CN¥268.21 Million
≈ $39.25 Million
+157.00%
2021-12-31 CN¥104.36 Million
≈ $15.27 Million
-52.76%
2020-12-31 CN¥220.94 Million
≈ $32.33 Million
+20.58%
2019-12-31 CN¥183.24 Million
≈ $26.81 Million
+31.32%
2018-12-31 CN¥139.53 Million
≈ $20.42 Million
+8.36%
2017-12-31 CN¥128.76 Million
≈ $18.84 Million
+41.61%
2016-12-31 CN¥90.93 Million
≈ $13.31 Million
-39.16%
2015-12-31 CN¥149.44 Million
≈ $21.87 Million
+67.36%
2014-12-31 CN¥89.30 Million
≈ $13.07 Million
+9.66%
2013-12-31 CN¥81.43 Million
≈ $11.92 Million
--

About Tibet Aim Pharm Inc

SHE:002826 China Drug Manufacturers - Specialty & Generic
Market Cap
$449.78 Million
CN¥3.07 Billion CNY
Market Cap Rank
#12648 Global
#3673 in China
Share Price
CN¥16.12
Change (1 day)
+0.06%
52-Week Range
CN¥15.01 - CN¥25.74
All Time High
CN¥32.76
About

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more